36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

NCT00258856 ·Status: COMPLETED ·Phase: PHASE2

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

NCT00643916 ·Status: COMPLETED ·Phase: PHASE2

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

NCT02864927 ·Status: COMPLETED ·Phase: PHASE4

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292 ·Status: COMPLETED ·Phase: PHASE3

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397 ·Status: COMPLETED ·Phase: PHASE3

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

NCT01270503 ·Status: COMPLETED ·Phase: PHASE4

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

NCT00262028 ·Status: COMPLETED ·Phase: PHASE2

A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

NCT01086969 ·Status: COMPLETED ·Phase: PHASE3

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

NCT01442675 ·Status: COMPLETED ·Phase: PHASE2

Immunology and Safety of Menactra® in Children in Saudi Arabia

NCT00539032 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation

NCT01890759 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

NCT00454909 ·Status: COMPLETED ·Phase: PHASE2

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

NCT00700713 ·Status: COMPLETED ·Phase: PHASE2

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

NCT00874549 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438 ·Status: COMPLETED ·Phase: PHASE3

Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

NCT00771849 ·Status: COMPLETED ·Phase: PHASE2

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

NCT02842853 ·Status: COMPLETED ·Phase: PHASE3

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

NCT02699840 ·Status: COMPLETED

Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults

NCT00772629 ·Status: TERMINATED ·Phase: PHASE2

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081 ·Status: COMPLETED ·Phase: PHASE2

Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

NCT01359449 ·Status: COMPLETED ·Phase: PHASE3

Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam

NCT02640404 ·Status: COMPLETED ·Phase: PHASE2

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277 ·Status: COMPLETED

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

NCT02633787 ·Status: COMPLETED ·Phase: PHASE4